GRPR-Antagonists Carrying DOTAGA-Chelator via Positively Charged Linkers: Perspectives for Prostate Cancer Theranostics
Gastrin-releasing peptide receptor (GRPR)-antagonists have served as motifs in the development of theranostic radioligands for prostate cancer. Our efforts have been focused on the development of radiolabeled RM26 (H-DPhe<sup>6</sup>-Gln<sup>7</sup>-Trp<sup>8</sup>...
Saved in:
Main Authors: | , , , , , , , |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_76e700bb020b4623bb32b8e8e73fddd6 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Karim Obeid |e author |
700 | 1 | 0 | |a Panagiotis Kanellopoulos |e author |
700 | 1 | 0 | |a Ayman Abouzayed |e author |
700 | 1 | 0 | |a Adam Mattsson |e author |
700 | 1 | 0 | |a Vladimir Tolmachev |e author |
700 | 1 | 0 | |a Berthold A. Nock |e author |
700 | 1 | 0 | |a Theodosia Maina |e author |
700 | 1 | 0 | |a Anna Orlova |e author |
245 | 0 | 0 | |a GRPR-Antagonists Carrying DOTAGA-Chelator via Positively Charged Linkers: Perspectives for Prostate Cancer Theranostics |
260 | |b MDPI AG, |c 2024-04-01T00:00:00Z. | ||
500 | |a 10.3390/pharmaceutics16040513 | ||
500 | |a 1999-4923 | ||
520 | |a Gastrin-releasing peptide receptor (GRPR)-antagonists have served as motifs in the development of theranostic radioligands for prostate cancer. Our efforts have been focused on the development of radiolabeled RM26 (H-DPhe<sup>6</sup>-Gln<sup>7</sup>-Trp<sup>8</sup>-Ala<sup>9</sup>-Val<sup>10</sup>-Gly<sup>11</sup>-His<sup>12</sup>-Sta<sup>13</sup>-Leu<sup>14</sup>-NH<sub>2</sub>) analogs, such as [<sup>111</sup>In]In-DOTAGA-PEG2-RM26. We recently showed that its Gly<sup>11</sup>/Sar<sup>11</sup>-substituted version, [<sup>111</sup>In]In-AU-RM26-M1, resisted degradation by neprilysin (NEP) while in circulation and achieved higher tumor uptake in mice. We herein introduce the following three new AU-RM26-M1 mimics labeled with In-111, with basic residues in the linker: (i) AU-RM26-M2 (PEG2-Pip), (ii) AU-RM26-M3 (PEG2-Arg), and (iii) AU-RM26-M4 (Arg-Arg-Pip). These analogs were compared in PC-3 cells and animal models vs. AU-RM26-M1 (reference). The new analogs showed high affinity and specificity for the GRPR, exhibiting an uptake and distribution pattern in PC-3 cells typical for a radiolabeled GRPR-antagonist. They showed high stability in peripheral mice blood, except for [<sup>111</sup>In]In-AU-RM26-M3. AU-RM26-M4 achieved the highest tumor uptake and promising background clearance, followed by [<sup>111</sup>In]In-RM26-M2, showing lower background levels. These findings were confirmed for [<sup>111</sup>In]In-AU-RM26-M2 and [<sup>111</sup>In]In-AU-RM26-M4 by micro-SPECT/CT at 4 and 24 h post-injection. Hence, the type of positively charged residues in the linker of AU-RM26-M1 mimics strongly influenced biological behavior. The analogs with Pip next to DPhe<sup>6</sup> demonstrated the best overall characteristics and warrant further investigation. | ||
546 | |a EN | ||
690 | |a prostate cancer | ||
690 | |a GRPR | ||
690 | |a GRPR-antagonist | ||
690 | |a radiotheranostics | ||
690 | |a PC-3 cell/tumor | ||
690 | |a neprilysin | ||
690 | |a Pharmacy and materia medica | ||
690 | |a RS1-441 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Pharmaceutics, Vol 16, Iss 4, p 513 (2024) | |
787 | 0 | |n https://www.mdpi.com/1999-4923/16/4/513 | |
787 | 0 | |n https://doaj.org/toc/1999-4923 | |
856 | 4 | 1 | |u https://doaj.org/article/76e700bb020b4623bb32b8e8e73fddd6 |z Connect to this object online. |